Hoth Therapeutics and Wise Systems International have teamed up to harness the power of artificial intelligence (AI) for drug discovery, leveraging the Nvidia BioNeMo generative AI platform. This collaboration aims to advance drug development pipelines and enhance the value of existing assets, reflecting a broader trend in the pharmaceutical industry towards AI-driven methodologies.
Hoth Therapeutics and Wise Systems International Partner to Utilise Artificial Intelligence in Drug Discovery
New York, June 10, 2024 — Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, has entered into a joint development agreement with Wise Systems International SRL. The collaboration aims to leverage artificial intelligence (AI) technology in drug discovery, utilising the Nvidia BioNeMo generative AI platform.
The BioNeMo AI platform is designed to assist researchers and developers in building and integrating advanced generative AI applications throughout the drug discovery process. This includes phases from target identification to lead optimization. Under the agreement, Hoth Therapeutics will use SRL’s expertise to enhance its drug development pipeline and increase the value of its existing assets.
Robert Antofe of Wise Systems International SRL expressed enthusiasm about the partnership, noting that leveraging their AI capabilities will add value to the initiatives of both companies. Robb Knie, CEO of Hoth Therapeutics, also acknowledged the potential benefits of the Nvidia BioNeMo platform, stating, “We believe the Nvidia BioNeMo platform is best in class and with SRL’s assistance we can better grow our intellectual property, leverage our existing pipeline, and deliver novel therapeutics to patients in need.”
Hoth Therapeutics’ focus is on developing innovative treatments aimed at improving patient quality of life. The company collaborates with scientists, clinicians, and key opinion leaders to advance drugs from early-stage research to clinical testing.
Using AI for drug discovery is a growing trend in the pharmaceutical industry. AI technologies can potentially accelerate the development process, reduce costs, and improve the accuracy of predictions about a drug’s efficacy and safety. While traditional drug discovery methods can take years and involve significant expenses, AI has the potential to streamline this process by rapidly analyzing large datasets and identifying promising drug candidates.
Nvidia BioNeMo is part of Nvidia’s suite of AI tools tailored for the healthcare and life sciences sectors. The platform aims to provide a robust and streamlined approach to integrating AI in drug discovery workflows, enabling researchers to handle complex tasks more efficiently.
This agreement between Hoth Therapeutics and Wise Systems International SRL aligns with broader industry efforts to incorporate advanced technologies into pharmaceutical research. As the field evolves, such partnerships may become increasingly common, reflecting a shift towards more AI-driven methodologies in drug development.
For more information, visit Hoth Therapeutics’ website at Hoth Therapeutics.
Contact Information:
LR Advisors LLC
Email: [email protected]
Phone: (678) 570-6791
Source: Hoth Therapeutics, Inc.
